Literature DB >> 19407023

The role of fractalkine as an accelerating factor on the autoimmune exocrinopathy in mice.

Kazuo Tsubota1, Tatsuaki Nishiyama, Kenji Mishima, Hiroko Inoue, Takeshi Doi, Yukio Hattori, Tatsuhiko Kodama, Akihiro Higuchi, Yoshio Hayashi, Ichiro Saito.   

Abstract

PURPOSE: Sjögren's syndrome (SS) is an organ-specific autoimmune disease caused by the progressive loss of exocrine glands and is associated with several autoimmune phenomena. Various research studies have been performed, and many molecules have been suggested as responsible for the pathogenesis of SS. Here the authors show the increased expression of fractalkine (CX(3)CL1) in lacrimal glands of SS model mice. Among more than 50 known chemokines, fractalkine is the sole member of the CX(3)C family and has unique structural and functional attributes. The purpose of this study was to analyze the role of fractalkine in exocrine glands.
METHODS: The expression of fractalkine in the lacrimal glands of thymectomized NFS/sld mice was investigated by immunohistochemistry and RT-PCR. To confirm the effects of fractalkine in exocrine glands, tissue-specific fractalkine transgenic mice were generated using the salivary amylase promoter.
RESULTS: The results demonstrated the upregulated fractalkine expression in thymectomized NFS/sld mice. Furthermore, the lacrimal and salivary gland-specific fractalkine transgenic mice showed the expression of fragmented fractalkine and lymphocytic infiltration in their lacrimal and submandibular glands. Interestingly, the dominant population was B cells in the lacrimal glands, whereas B cells and CD4(+) T cells were infiltrated in the submandibular glands. These mice also demonstrated slightly decreased tear and salivary secretion compared with wild-type mice.
CONCLUSIONS: Based on these results, it may be that fractalkine contributes to the development of SS, especially in lymphocyte migration to exocrine glands, and that it accelerates the disease in association with other molecules.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19407023     DOI: 10.1167/iovs.08-2596

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  7 in total

Review 1.  The emergence of ADAM10 as a regulator of lymphocyte development and autoimmunity.

Authors:  David R Gibb; Sheinei J Saleem; Natalia S Chaimowitz; Joel Mathews; Daniel H Conrad
Journal:  Mol Immunol       Date:  2011-01-13       Impact factor: 4.407

2.  Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease.

Authors:  Amalia Enríquez-de-Salamanca; Evangelina Castellanos; Michael E Stern; Itziar Fernández; Ester Carreño; Carmen García-Vázquez; Jose M Herreras; Margarita Calonge
Journal:  Mol Vis       Date:  2010-05-19       Impact factor: 2.367

3.  Fractalkine/CX3CL1 protects striatal neurons from synergistic morphine and HIV-1 Tat-induced dendritic losses and death.

Authors:  Masami Suzuki; Nazira El-Hage; Shiping Zou; Yun-Kyung Hahn; Mary E Sorrell; Jamie L Sturgill; Daniel H Conrad; Pamela E Knapp; Kurt F Hauser
Journal:  Mol Neurodegener       Date:  2011-11-17       Impact factor: 14.195

4.  Salivary Gland Derived BDNF Overexpression in Mice Exerts an Anxiolytic Effect.

Authors:  Juri Saruta; Masahiro To; Masahiro Sugimoto; Yuko Yamamoto; Tomoko Shimizu; Yusuke Nakagawa; Hiroko Inoue; Ichiro Saito; Keiichi Tsukinoki
Journal:  Int J Mol Sci       Date:  2017-09-05       Impact factor: 5.923

5.  Pathological role of fractalkine/CX3CL1 in rheumatic diseases: a unique chemokine with multiple functions.

Authors:  Brian Jones; Alisa E Koch; Salahuddin Ahmed
Journal:  Front Immunol       Date:  2012-01-02       Impact factor: 7.561

Review 6.  The clearance of dying cells: table for two.

Authors:  D R Green; T H Oguin; J Martinez
Journal:  Cell Death Differ       Date:  2016-03-18       Impact factor: 15.828

7.  Emergent role of the fractalkine axis in dissemination of peritoneal metastasis from epithelial ovarian carcinoma.

Authors:  H Gurler Main; J Xie; G G Muralidhar; O Elfituri; H Xu; A A Kajdacsy-Balla; M V Barbolina
Journal:  Oncogene       Date:  2016-12-12       Impact factor: 9.867

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.